ANIK Anika Therapeutics Inc.

Anika to Issue Fourth Quarter and Year-End 2020 Financial Results on Thursday, March 4, 2021

Anika to Issue Fourth Quarter and Year-End 2020 Financial Results on Thursday, March 4, 2021

BEDFORD, Mass., Feb. 09, 2021 (GLOBE NEWSWIRE) -- (NASDAQ: ANIK), a global joint preservation company that creates and delivers meaningful advancements in early intervention orthopedic care, today announced that the Company plans to issue its fourth quarter and year-end 2020 financial results after the close of the market on Thursday, March 4, 2021 and hold its investor conference call and webcast on the same day, at 5:00 p.m. ET to discuss its financial results and business highlights.

The conference call can be accessed by dialing 1-855-327-6837 (toll-free domestic) or 1-631-891-4304 (international) and providing the conference ID number 10012940. A live audio webcast will be available in the section of Anika's website, . An accompanying slide presentation also can be accessed via the Anika investor relations website. The call will be archived and accessible on the same website shortly after its conclusion.

About Anika Therapeutics, Inc.

 (NASDAQ: ANIK), is a global joint preservation company that creates and delivers meaningful advancements in early intervention orthopedic care. We partner with physicians to understand what they need most to treat their patients and we develop minimally invasive products that restore active living for people around the world. We are committed to leading in high opportunity spaces within orthopedics, including osteoarthritis pain management, regenerative solutions, soft tissue repair and bone preserving joint technologies. For more information, please visit .

For Investor Inquiries:

Anika Therapeutics, Inc.

Mark Namaroff, 781-457-9287

Executive Director, Investor Relations and Corporate Communications



EN
09/02/2021

Underlying

ANIKAnika Therapeutics Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Anika Therapeutics Inc.

 PRESS RELEASE
Free
ANIK Anika Therapeut...

Anika Reports Second Quarter 2025 Financial Results

Anika Reports Second Quarter 2025 Financial Results Regenerative Solutions revenue up 41% with Integrity™ Implant System ahead of expectations and continued strong Hyalofast® growth; Integrity surpasses full year 2024 performance and is on pace to more than double in 2025 Company released topline results for Hyalofast® clinical trial which did not meet pre-specified co-primary end points; Hyalofast demonstrated statistically significant improvements in pre-defined secondary endpoints and other measures; Company plans to file the final PMA module in second half 2025 Reaffirming Fis...

July 30, 2025 1 EN
 PRESS RELEASE
Free
ANIK Anika Therapeut...

Anika Reports Topline Results from U.S. Pivotal FastTRACK Phase III St...

Anika Reports Topline Results from U.S. Pivotal FastTRACK Phase III Study for Hyalofast® Cartilage Repair Scaffold and Provides Program Update Hyalofast consistently demonstrated improvements over microfracture, but missed on statistical significance of the pre-specified co-primary endpoints of percent change in KOOS Pain and IKDC function Hyalofast showed statistically significant improvements over microfracture in pre-defined secondary endpoints and other measures that align with prior FDA approvals for cartilage repair products Hyalofast has been used to treat over 35,000 pati...

July 30, 2025 1 EN
 PRESS RELEASE
Free
ANIK Anika Therapeut...

Anika to Issue Second Quarter 2025 Financial Results on Wednesday, Jul...

Anika to Issue Second Quarter 2025 Financial Results on Wednesday, July 30, 2025 BEDFORD, Mass., July 16, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, announced today that it will issue its second quarter 2025 financial results before the opening of the market on Wednesday, July 30, 2025, followed by a conference call at 8:30 a.m. ET to discuss its results and business highlights. The conference call can be accessed by dialing 1-800-717-1738 (toll-free domestic) or 1-646-307-1865 (international) and providing the confere...

July 16, 2025 1 EN
 PRESS RELEASE
Free
ANIK Anika Therapeut...

Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BEDFORD, Mass., July 03, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: ANIK), a global leader in the osteoarthritis pain management and regenerative solutions spaces focused on early intervention orthopedics, today announced that on July 1, 2025, Anika granted non-statutory stock options (“Options”) covering an aggregate of 2,500 shares of common stock at a per share exercise price of $10.53, which equaled the closing price of common stock on the Nasdaq Global Select Market (“Closing Price”) on the grant date, to one newly hired no...

July 3, 2025 1 EN
 PRESS RELEASE
Free
ANIK Anika Therapeut...

Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BEDFORD, Mass., June 05, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: ANIK), a global leader in the osteoarthritis pain management and regenerative solutions spaces focused on early intervention orthopedics, today announced that on June 2, 2025, Anika granted non-statutory stock options (“Options”) covering an aggregate of 2,500 shares of common stock at a per share exercise price of $11.45, which equaled the closing price of common stock on the Nasdaq Global Select Market (“Closing Price”) on the grant date, to one newly hired no...

June 5, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch